Merck makes haste to catch up in KRAS
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
New listings reveal expanded phase 3 programmes for J&J’s Talvey and Amgen’s tarlatamab.
As the biotech markets turned bullish the sector’s ups and downs continued.
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.